Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 1.00 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823646 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACRBN | |
| Cyclohexanone SCHEMBL386409 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACRBN | |
| Cyclohexanone SCHEMBL3299 | 1.00 | — | — | |
| Cycloheptanone SCHEMBL6077 | 1.00 | — | — | |
| SCHEMBL1905857 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACRBN | |
| SCHEMBL21403465 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACRBN | |
| SCHEMBL25380098 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACRBN | |
| SCHEMBL112034 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACRBN | |
| SCHEMBL1667004 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACRBN | |
| Cyclohexanone SCHEMBL713141 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391597-B1 | METHOD FOR PRODUCING PURE CYCLODODECANONE | BASF SE (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-8188320-B2 | Process for preparing pure cyclododecanone | BASF SE (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20100191018-A1 | PROCESS FOR PREPARING PURE CYCLODODECANONE | BASF SE (DE) | 2010-07-29 | — | — | US | disclosed |
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100191018-A1 | PROCESS FOR PREPARING PURE CYCLODODECANONE | CCNA1, CYC1, CCNA2 | TRIM24 3392/4885TRIM33 4369/4885ALDH1A1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.